HBAN announces that Bluedrop Medical, a Galway based Medical device start up, has secured €3.7M in funding to help manage one of the most devastating complications of diabetes – the diabetic foot. An initial seed investment of €1.2M was led by HBAN’s MedTech Syndicate - which itself invested €340K in the seed round. Enterprise Ireland and the Western Development Commission also invested in the funding round along with other members of the investment community. A €2.5M grant was awarded through the European Innovation Council.
The issue of gender equality in the business world is not a new one but in recent times we have started to see constructive debate gaining traction. While it is sadly still not uncommon to hear stories of successful, qualified women being paid less or being overlooked for promotions, such cases are now at least being called out and given prominence rather than swept under the carpet and accepted as the norm.
On the 17th of September, 500 professionals working in the business of sport will gather at Dublin’s Aviva Stadium for One-Zero's SportsTech conference to learn, network and help shape the future. A lineup of 40+ international speakers will address an audience of ‘change-makers’, delivering world-class insights across four key sectors and stages.
One of the biggest challenges faced by early stage investors is to assemble a portfolio of investments that in aggregate return more than 2 times the original amount invested in the total portfolio. In the language of Venture Capital, the goal of a successful early stage investor is to achieve a Distributed to Paid-In (DPI) ratio greater than 2X. In other words, for every dollar you invest in your portfolio, you want to get two dollars back over time. And, if you want to be one of the top decile early stage investors, you want to shoot for a DPI of 3X or greater to be one of the top decile early stage investors, you want to shoot for a DPI of 3X or greater.
If you‘re a high potential Start Up that has a new innovative product or service ready for commercialisation and/or have achieved some early traction and are raising finance to scale internationally please contact us.